Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nilotinib.

× No keyword cloud information.

22 in total

1. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Bryan C Disch; Jessica E Thorpe; Anja Bastian; Michael A Ihnat
Journal: Bioorg Med Chem Date: 2013-01-31 Impact factor: 3.641

2. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Authors: A Megan Cornelison; Hagop Kantarjian; Jorge Cortes; Elias Jabbour
Journal: Clin Lymphoma Myeloma Leuk Date: 2011-04-28

3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors: Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal: Clin Pharmacokinet Date: 2011-09 Impact factor: 6.447

4. Nilotinib protects the murine liver from ischemia/reperfusion injury.

Authors: Lee M Ocuin; Shan Zeng; Michael J Cavnar; Eric C Sorenson; Zubin M Bamboat; Jonathan B Greer; Teresa S Kim; Rachel Popow; Ronald P DeMatteo
Journal: J Hepatol Date: 2012-05-26 Impact factor: 25.083

5. Activation of abl family kinases in solid tumors.

Authors: Sourik S Ganguly; Rina Plattner
Journal: Genes Cancer Date: 2012-05

Review 6. High-risk childhood acute lymphoblastic leukemia.

Authors: Deepa Bhojwani; Scott C Howard; Ching-Hon Pui
Journal: Clin Lymphoma Myeloma Date: 2009

7. Management of imatinib-resistant patients with chronic myeloid leukemia.

Authors: Pavan Kumar Bhamidipati; Hagop Kantarjian; Jorge Cortes; A Megan Cornelison; Elias Jabbour
Journal: Ther Adv Hematol Date: 2013-04

Review 8. Renal toxicity of targeted therapies.

Authors: Ronan J Kelly; Bertrand Billemont; Olivier Rixe
Journal: Target Oncol Date: 2009-05-06 Impact factor: 4.493

Review 9. Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

Authors: Rafał Stec; Bartłomiej Grala; Michał Maczewski; Lubomir Bodnar; Cezary Szczylik
Journal: J Exp Clin Cancer Res Date: 2009-10-07

Review 10. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Authors: Kevin Kelly; Ronan Swords; Devalingam Mahalingam; Swaminathan Padmanabhan; Francis J Giles
Journal: Target Oncol Date: 2009-04-21 Impact factor: 4.493